Dynamic Technology Lab Private Ltd Makes New Investment in Personalis, Inc. (NASDAQ:PSNL)

Dynamic Technology Lab Private Ltd purchased a new stake in Personalis, Inc. (NASDAQ:PSNL) during the fourth quarter, Holdings Channel reports. The fund purchased 43,685 shares of the company’s stock, valued at approximately $252,000.

Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in shares of Personalis by 2,827.0% in the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company’s stock valued at $34,000 after purchasing an additional 5,654 shares during the period. Olympiad Research LP purchased a new position in Personalis in the fourth quarter valued at $59,000. SG Americas Securities LLC purchased a new position in shares of Personalis in the 4th quarter valued at about $63,000. Raymond James Financial Inc. acquired a new position in Personalis in the fourth quarter valued at approximately $64,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Personalis in the fourth quarter valued at approximately $87,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Personalis Price Performance

PSNL stock opened at $3.03 on Friday. The company has a market cap of $267.44 million, a price-to-earnings ratio of -1.80 and a beta of 1.89. The company has a fifty day moving average price of $4.12 and a 200 day moving average price of $4.62. Personalis, Inc. has a 12 month low of $1.14 and a 12 month high of $7.20.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, February 27th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.09. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The business had revenue of $16.80 million during the quarter, compared to analysts’ expectations of $15.48 million. As a group, analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PSNL. Needham & Company LLC restated a “buy” rating and set a $7.00 price objective on shares of Personalis in a research report on Thursday. Lake Street Capital upped their price objective on shares of Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Craig Hallum initiated coverage on Personalis in a report on Monday, March 17th. They set a “buy” rating and a $8.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Personalis in a report on Friday, February 28th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $7.80.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.